4.7 Article

Targeting HER2 mutation–positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT basket trial.

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 40, Issue 16_suppl, Pages 4079-4079

Publisher

American Society of Clinical Oncology (ASCO)
DOI: 10.1200/jco.2022.40.16_suppl.4079

Keywords

-

Categories

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available